Literature DB >> 14612531

Fatty acid synthase inhibition triggers apoptosis during S phase in human cancer cells.

Weibo Zhou1, P Jeanette Simpson, Jill M McFadden, Craig A Townsend, Susan M Medghalchi, Aravinda Vadlamudi, Michael L Pinn, Gabriele V Ronnett, Francis P Kuhajda.   

Abstract

C75, an inhibitor of fatty acid synthase (FAS), induces apoptosis in cultured human cancer cells. Its proposed mechanism of action linked high levels of malonyl-CoA after FAS inhibition to potential downstream effects including inhibition of carnitine palmitoyltransferase-1 (CPT-1) with resultant inhibition of fatty acid oxidation. Recent data has shown that C75 directly stimulates CPT-1 increasing fatty acid oxidation in MCF-7 human breast cancer cells despite inhibitory concentrations of malonyl-CoA. In light of these findings, we have studied fatty acid metabolism in MCF7 human breast cancer cells to elucidate the mechanism of action of C75. We now report that: (a) in the setting of increased fatty acid oxidation, C75 inhibits fatty acid synthesis; (b) C273, a reduced form of C75, is unable to inhibit fatty acid synthesis and is nontoxic to MCF7 cells; (c) C75 and 5-(tetradecyloxy)-2-furoic acid (TOFA), an inhibitor of acetyl-CoA carboxylase, both cause a significant reduction of fatty acid incorporation into phosphatidylcholine, the major membrane phospholipid, within 2 h; (d) pulse chase studies with [(14)C]acetate labeling of membrane lipids show that both C75 and TOFA accelerate the decay of (14)C-labeled lipid from membranes within 2 h; (e) C75 also promotes a 2-3-fold increase in oxidation of membrane lipids within 2 h; and (f) because interference with phospholipid synthesis during S phase is known to trigger apoptosis in cycling cells, we performed double-labeled terminal deoxynucleotidyltransferase-mediated nick end labeling and BrdUrd analysis with both TOFA and C75. C75 triggered apoptosis during S phase, whereas TOFA did not. Moreover, application of TOFA 2 h before C75 blocked the C75 induced apoptosis, whereas etomoxir did not. Taken together these data indicate that FAS inhibition and its downstream inhibition of phospholipid production is a necessary part of the mechanism of action of C75. CPT-1 stimulation does not likely play a role in the cytotoxic response. The continued ability of TOFA to rescue cancer cells from C75 cytotoxicity implies a proapoptotic role for malonyl-CoA independent of CPT-1 that selectively targets cancer cells as they progress into S phase.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14612531

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  76 in total

1.  Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.

Authors:  Abir Mukherjee; Jinhua Wu; Suzanne Barbour; Xianjun Fang
Journal:  J Biol Chem       Date:  2012-06-03       Impact factor: 5.157

2.  AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress.

Authors:  Sang-Min Jeon; Navdeep S Chandel; Nissim Hay
Journal:  Nature       Date:  2012-05-09       Impact factor: 49.962

Review 3.  Targeting Cancer Metabolism and Current Anti-Cancer Drugs.

Authors:  Witchuda Sukjoi; Jarunya Ngamkham; Paul V Attwood; Sarawut Jitrapakdee
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Genome-wide association study provides evidence for a breast cancer risk locus at 6q22.33.

Authors:  Bert Gold; Tomas Kirchhoff; Stefan Stefanov; James Lautenberger; Agnes Viale; Judy Garber; Eitan Friedman; Steven Narod; Adam B Olshen; Peter Gregersen; Kristi Kosarin; Adam Olsh; Julie Bergeron; Nathan A Ellis; Robert J Klein; Andrew G Clark; Larry Norton; Michael Dean; Jeff Boyd; Kenneth Offit
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-07       Impact factor: 11.205

5.  Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.

Authors:  Joshua J Souchek; Amanda L Davis; Tanner K Hill; Megan B Holmes; Bowen Qi; Pankaj K Singh; Steven J Kridel; Aaron M Mohs
Journal:  Mol Cancer Ther       Date:  2017-06-14       Impact factor: 6.261

6.  Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator.

Authors:  Kuen-Haur Lee; En-Chi Hsu; Jih-Hwa Guh; Hsiao-Ching Yang; Dasheng Wang; Samuel K Kulp; Charles L Shapiro; Ching-Shih Chen
Journal:  J Biol Chem       Date:  2011-09-14       Impact factor: 5.157

7.  A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.

Authors:  Mingzhao Zhu; Wayne D Harshbarger; Omar Robles; Joanna Krysiak; Kenneth G Hull; Sung Wook Cho; Robyn D Richardson; Yanyan Yang; Andres Garcia; Lindsey Spiegelman; Bianca Ramirez; Christopher T Wilson; Ju Anne Yau; James T Moore; Caitlen B Walker; James C Sacchettini; Wenshe R Liu; Stephan A Sieber; Jeffrey W Smith; Daniel Romo
Journal:  Bioorg Med Chem       Date:  2017-01-19       Impact factor: 3.641

Review 8.  Metabolic Regulation of Apoptosis in Cancer.

Authors:  K Matsuura; K Canfield; W Feng; M Kurokawa
Journal:  Int Rev Cell Mol Biol       Date:  2016-07-30       Impact factor: 6.813

9.  Role of fatty-acid synthesis in dendritic cell generation and function.

Authors:  Adeel Rehman; Keith C Hemmert; Atsuo Ochi; Mohsin Jamal; Justin R Henning; Rocky Barilla; Juan P Quesada; Constantinos P Zambirinis; Kerry Tang; Melvin Ego-Osuala; Raghavendra S Rao; Stephanie Greco; Michael Deutsch; Suchithra Narayan; H Leon Pachter; Christopher S Graffeo; Devrim Acehan; George Miller
Journal:  J Immunol       Date:  2013-03-27       Impact factor: 5.422

10.  The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women.

Authors:  Tal Distelman Menachem; Yael Laitman; Bella Kaufman; Eitan Friedman
Journal:  Fam Cancer       Date:  2009-06-11       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.